compounding pharmacies

The Department of Health and Human Services will permit pharmacies to compound popular peptides that lack FDA approval, according to NPR. The policy shift affects widely used compounds often marketed for weight loss, recovery and anti-ageing, and is drawing attention from both patients who rely on them and critics who question safety oversight of drugs that have not gone through standard approval.

The Trump administration is permitting compounding pharmacies to produce six peptides that have not been approved by the FDA. The decision green-lights compounds that would normally face federal clearance, though demand for the substances may quickly outpace the available supply. The move is drawing attention in health and wellness circles, where debate is likely over safety oversight versus access to these increasingly popular compounds.

The Trump administration will allow compounding pharmacies to produce six peptides that have not received federal approval, easing enforcement rules for these drugs. The move green-lights wider availability of substances often used in wellness and weight-loss circles, and is drawing attention because unapproved peptides bypass standard FDA review. Supporters see it as expanding access; critics warn about safety and oversight.

The Trump administration will permit pharmacies to produce popular peptides, a category of compounds widely used for weight loss, anti-aging and other health purposes. The move, reported by NPR, loosens restrictions on compounding these drugs and could expand patient access while drawing scrutiny over safety and regulation.